Insmed (INSM) EBITDA Margin (2010 - 2026)
Insmed (INSM) posted quarterly EBITDA Margin of 50.11% for Q1 2026, up 21722.0% year-over-year from N/an in Q1 2025, and up 58.65% quarter-over-quarter from 121.19% in Q4 2025.
Insmed (INSM) EBITDA Margin (2010 - 2026) Analysis & Trends
Insmed's EBITDA Margin history runs 12 years deep, the most recent figure standing at 50.11% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 21722.0% year-over-year to 50.11%; the TTM figure through Mar 2026 stood at 140.56% (up 11687.0% YoY), while the FY2025 annual figure was 205.59%, up 3588.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 50.11%, up from 121.19% in the prior quarter.
- The five-year high for EBITDA Margin was 50.11% in Q1 2026, with the low at 319.8% in Q2 2024.
- The 5-year median for EBITDA Margin is 220.61% (2024), against an average of 213.48%.
- The sharpest annual moves came in 2023 and 2026: EBITDA Margin plunged 16956 bps in 2023, then soared 21722 bps in 2026.
- Insmed's EBITDA Margin stood at 255.44% in 2022, then rose by 17 bps to 213.01% in 2023, then dropped by 4 bps to 220.61% in 2024, then surged by 45 bps to 121.19% in 2025, then soared by 59 bps to 50.11% in 2026.
- Business Quant data shows INSM's EBITDA Margin at 50.11% in Q1 2026, 121.19% in Q4 2025, and 257.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.36% |
| Mar 31, 2026 | -50.11% |
| Dec 31, 2025 | -121.19% |
| Sep 30, 2025 | -257.13% |
| Jun 30, 2025 | -291.28% |
| Mar 31, 2025 | -267.33% |
| Dec 31, 2024 | -220.61% |
| Sep 30, 2024 | -228.45% |
| Jun 30, 2024 | -319.80% |
| Mar 31, 2024 | -192.72% |
| Dec 31, 2023 | -213.01% |
| Sep 30, 2023 | -186.75% |
| Jun 30, 2023 | -304.97% |
| Mar 31, 2023 | -227.19% |
| Dec 31, 2022 | -255.44% |
| Sep 30, 2022 | -188.54% |
| Jun 30, 2022 | -135.41% |
| Mar 31, 2022 | -169.15% |
| Dec 31, 2021 | -176.53% |
| Sep 30, 2021 | -221.61% |